Share This Article:

The Emerging Role of Statins in Glaucoma Pathological Mechanisms and Therapeutics

Abstract Full-Text HTML XML Download Download as PDF (Size:3429KB) PP. 124-138
DOI: 10.4236/ojoph.2014.44021    3,990 Downloads   4,671 Views   Citations


Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and hence have a profound effect in lowering serum cholesterol. Their predominant clinical use to date is in primary and secondary prevention of cardiovascular disease. However recently interest has developed regarding the so-called “pleiotropic” effects of statins—these drugs have significant anti-fibrotic, anti-inflammatory, and immunomodulatory properties. Such effects of statins have already been shown to be beneficial in modulating the pathological mechanisms involved in pul-monary fibrosis, renal disease, non-ischaemic cardiac failure, and tissue scarring. Many of these actions are mediated by inhibition of the Rho kinase pathway. Epidemiological studies suggest that patients who take statins have a lower risk of developing glaucoma, and lower rates of glaucoma progression. Here, we review what is known about the pleiotropic effect of statins to date, and examine how these effects may modulate the molecular mechanisms involved in glaucoma pathogenesis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Pokrovskaya, O. , Wallace, D. and O’Brien, C. (2014) The Emerging Role of Statins in Glaucoma Pathological Mechanisms and Therapeutics. Open Journal of Ophthalmology, 4, 124-138. doi: 10.4236/ojoph.2014.44021.


[1] Stein, J.D., et al. (2012) The Relationship between Statin Use and Open-Angle Glaucoma. Ophthalmology, 119, 2074-2081.
[2] Leung, D.Y., et al. (2010) Simvastatin and Disease Stabilization in Normal Tension Glaucoma: A Cohort Study. Ophthalmology, 117, 471-476.
[3] Schmeer, C., Kretz, A. and Isenmann, S. (2006) Statin-Mediated Protective Effects in the Central Nervous System: General Mechanisms and Putative Role of Stress Proteins. Restorative Neurology and Neuroscience, 24, 79-95.
[4] Chen, C.H., et al. (2013) Rosuvastatin Inhibits Pressure-Induced Fibrotic Responses via the Expression Regulation of Prostacyclin and Prostaglandin E2 in Rat Renal Tubular Cells. European Journal of Pharmacology, 700, 65-73.
[5] Schaafsma, D., et al. (2011) Simvastatin Inhibits TGFbeta1-Induced Fibronectin in Human Airway Fibroblasts. Respiratory Research, 12, 113.
[6] Watts, K.L., et al. (2005) Simvastatin Inhibits Growth Factor Expression and Modulates Profibrogenic Markers in Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 32, 290-300.
[7] Cordle, A., et al. (2005) Mechanisms of Statin-Mediated Inhibition of Small G-Protein Function. Journal of Biological Chemistry, 280, 34202-34209.
[8] Laufs, U., et al. (2000) Neuroprotection Mediated by Changes in the Endothelial Actin Cytoskeleton. Journal of Clinical Investigation, 106, 15-24.
[9] Kato, T., et al. (2004) Statin Blocks Rho/Rho-Kinase Signalling and Disrupts the Actin Cytoskeleton: Relationship to Enhancement of LPS-Mediated Nitric Oxide Synthesis in Vascular Smooth Muscle Cells. Biochimica et Biophysica Acta, 1689, 267-272.
[10] Quigley, H.A., et al. (1981) Optic Nerve Damage in Human Glaucoma. II. The Site of Injury and Susceptibility to Damage. Archives of Ophthalmology, 99, 635-649.
[11] Quigley, H.A. and Broman, A.T. (2006) The Number of People with Glaucoma Worldwide in 2010 and 2020. British Journal of Ophthalmology, 90, 262-267.
[12] Lambert, W., et al. (2001) Neurotrophin and Neurotrophin Receptor Expression by Cells of the Human Lamina Cribrosa. Investigative Ophthalmology & Visual Science, 42, 2315-2323.
[13] Cassard, S.D., et al. (2012) Regional Variations and Trends in the Prevalence of Diagnosed Glaucoma in the Medicare Population. Ophthalmology, 119, 1342-1351.
[14] Hernandez, M.R. and Pena, J.D. (1997) The Optic Nerve Head in Glaucomatous Optic Neuropathy. Archives of Ophthalmology, 115, 389-395.
[15] Hernandez, M.R., Andrzejewska, W.M. and Neufeld, A.H. (1990) Changes in the Extracellular Matrix of the Human Optic Nerve Head in Primary Open-Angle Glaucoma. American Journal of Ophthalmology, 109, 180-188.
[16] Roberts, M.D., et al. (2010) Changes in the Biomechanical Response of the Optic Nerve Head in Early Experimental Glaucoma. Investigative Ophthalmology & Visual Science, 51, 5675-5684.
[17] Fautsch, M.P. and Johnson, D.H. (2006) Aqueous Humor Outflow: What Do We Know? Where Will It Lead Us? Investigative Ophthalmology & Visual Science, 47, 4181-4187.
[18] Johnson, M. (2006) What Controls Aqueous Humour Outflow Resistance? Experimental Eye Research, 82, 545-557.
[19] Kirwan, R.P., et al. (2009) Differential Global and Extra-Cellular Matrix Focused Gene Expression Patterns between Normal and Glaucomatous Human Lamina Cribrosa Cells. Molecular Vision, 15, 76-88.
[20] Liu, Y., et al. (2013) Gene Expression Profile in Human Trabecular Meshwork with Primary Open Angle Glaucoma. Investigative Ophthalmology & Visual Science, 54, 6382-6389.
[21] Coleman, A.L., et al. (1991) Displacement of the Optic Nerve Head by Acute Changes in Intraocular Pressure in Monkey Eyes. Ophthalmology, 98, 35-40.
[22] Hernandez, M.R. (1992) Ultrastructural Immunocytochemical Analysis of Elastin in the Human Lamina Cribrosa. Changes in Elastic Fibers in Primary Open-Angle Glaucoma. Investigative Ophthalmology & Visual Science, 33, 2891-2903.
[23] Quigley, H.A., et al. (2000) Retrograde Axonal Transport of BDNF in Retinal Ganglion Cells Is Blocked by Acute IOP Elevation in Rats. Investigative Ophthalmology & Visual Science, 41, 3460-3466.
[24] Hernandez, M.R., Igoe, F. and Neufeld, A.H. (1988) Cell Culture of the Human Lamina Cribrosa. Investigative Ophthalmology & Visual Science, 29, 78-89.
[25] Kirwan, R.P., et al. (2005) Influence of Cyclical Mechanical Strain on Extracellular Matrix Gene Expression in Human Lamina Cribrosa Cells in Vitro. Molecular Vision, 11, 798-810.
[26] Kirwan, R.P., et al. (2005) Transforming Growth Factor-Beta-Regulated Gene Transcription and Protein Expression in Human GFAP-Negative Lamina Cribrosa Cells. Glia, 52, 309-324.
[27] Quill, B., et al. (2011) The Effect of Graded Cyclic Stretching on Extracellular Matrix-Related Gene Expression Profiles in Cultured Primary Human Lamina Cribrosa Cells. Investigative Ophthalmology & Visual Science, 52, 1908-1915.
[28] Wallace, D.M., et al. (2013) Anti-Connective Tissue Growth Factor Antibody Treatment Reduces Extracellular Matrix Production in Trabecular Meshwork and Lamina Cribrosa Cells. Investigative Ophthalmology & Visual Science, 54, 7836-7848.
[29] Pattabiraman, P.P., Maddala, R. and Rao, P.V. (2014) Regulation of Plasticity and Fibrogenic Activity of Trabecular Meshwork Cells by Rho GTPase Signaling. Journal of Cellular Physiology, 229, 927-942.
[30] Honjo, M., et al. (2001) Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility. Investigative Ophthalmology & Visual Science, 42, 137-144.
[31] Tanihara, H., et al. (2013) Phase 2 Randomized Clinical Study of a Rho Kinase Inhibitor, K-115, in Primary Open-Angle Glaucoma and Ocular Hypertension. American Journal of Ophthalmology, 156, 731-736.
[32] Goldstein, J.L. and Brown, M.S. (1990) Regulation of the Mevalonate Pathway. Nature, 343, 425-430.
[33] Van Aelst, L. and D’Souza-Schorey, C. (1997) Rho GTPases and Signaling Networks. Genes Development, 11, 2295-2322.
[34] Burridge, K. and Wennerberg, K. (2004) Rho and Rac Take Center Stage. Cell, 116, 167-179.
[35] Gaw, A. (2000) Statins: The HMG CoA Reductase Inhibitors in Perspective. Martin Dunitz Ltd.
[36] Cilla Jr., D.D., et al. (1996) Pharmacodynamic Effects and Pharmacokinetics of Atorvastatin after Administration to Normocholesterolemic Subjects in the Morning and Evening. The Journal of Clinical Pharmacology, 36, 604-609.
[37] Tse, F.L., Jaffe, J.M. and Troendle, A. (1992) Pharmacokinetics of Fluvastatin after Single and Multiple Doses in Normal Volunteers. The Journal of Clinical Pharmacology, 32, 630-638.
[38] Pan, H.Y., et al. (1990) Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin. The Journal of Clinical Pharmacology, 30, 1128-1135.
[39] Kajinami, K., Mabuchi, H. and Saito, Y. (2000) NK-104: A Novel Synthetic HMG-CoA Reductase Inhibitor. Expert Opinion on Investigational Drugs, 9, 2653-2661.
[40] Bottorff, M. and Hansten, P. (2000) Long-Term Safety of Hepatic Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors: The Role of Metabolism-Monograph for Physicians. Archives of Internal Medicine, 160, 2273-2280.
[41] Knopp, R.H. (1999) Drug Treatment of Lipid Disorders. The New England Journal of Medicine, 341, 498-511.
[42] McKenney, J.M., et al. (2003) Comparison of the Efficacy of Rosuvastatin versus Atorvastatin, Simvastatin, and Pravastatin in Achieving Lipid Goals: Results from the STELLAR Trial. Current Medical Research and Opinion, 19, 689-698.
[43] Olsson, A.G., et al. (2001) Effect of Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients with Hypercholesterolemia. American Journal of Cardiology, 88, 504-508.
[44] Black, D.M. (2002) A General Assessment of the Safety of HMG CoA Reductase Inhibitors (Statins). Current Atherosclerosis Reports, 4, 34-41.
[45] Ballantyne, C.M., et al. (2003) Risk for Myopathy with Statin Therapy in High-Risk Patients. Archives of Internal Medicine, 163, 553-564.
[46] Scandinavian Simvastatin Survival Study Group (1994) Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S). The Lancet, 344, 1383-1389.
[47] Shepherd, J., et al. (1995) Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England Journal of Medicine, 333, 1301-1307.
[48] Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. The Lancet, 360, 7-22.
[49] Horwich, T.B., MacLellan, W.R. and Fonarow, G.C. (2004) Statin Therapy Is Associated with Improved Survival in Ischemic and Non-Ischemic Heart Failure. Journal of the American College of Cardiology, 43, 642-648.
[50] Wassmann, S., et al. (2001) Inhibition of Geranylgeranylation Reduces Angiotensin II-Mediated Free Radical Production in Vascular Smooth Muscle Cells: Involvement of Angiotensin AT1 Receptor Expression and Rac1 GTPase. Molecular Pharmacology, 59, 646-654.
[51] Liu, M., et al. (2009) Atorvastatin Improves Endothelial Function and Cardiac Performance in Patients with Dilated Cardiomyopathy: The Role of Inflammation. Cardiovascular Drugs and Therapy, 23, 369-376.
[52] Landmesser, U., et al. (2005) Simvastatin versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans. Circulation, 111, 2356-2363.
[53] Gil-Nunez, A.C. and Villanueva, J.A. (2001) Advantages of Lipid-Lowering Therapy in Cerebral Ischemia: Role of HMG-CoA Reductase Inhibitors. Cerebrovascular Diseases, 11, 85-95.
[54] Vaughan, C.J., Delanty, N. and Basson, C.T. (2001) Statin Therapy and Stroke Prevention. Current Opinion in Cardiology, 16, 219-224.
[55] Mancini, G.B., et al. (2006) Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients with Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology, 47, 2554-2560.
[56] Soyseth, V., et al. (2007) Statin Use Is Associated with Reduced Mortality in COPD. European Respiratory Journal, 29, 279-283.
[57] Murphy, D.M., et al. (2008) Simvastatin Attenuates Release of Neutrophilic and Remodeling Factors from Primary Bronchial Epithelial Cells Derived from Stable Lung Transplant Recipients. American Journal of Physiology-Lung Cellular and Molecular Physiology, 294, L592-L599.
[58] Ito, T., et al. (2002) Regulation of Interleukin-8 Expression by HMG-CoA Reductase Inhibitors in Human Vascular Smooth Muscle Cells. Atherosclerosis, 165, 51-55.
[59] Newton, C.J., et al. (2002) Statin-Induced Apoptosis of Vascular Endothelial Cells Is Blocked by Dexamethasone. Journal of Endocrinology, 174, 7-16.
[60] Shishehbor, M.H., et al. (2003) Statins Promote Potent Systemic Antioxidant Effects through Specific Inflammatory Pathways. Circulation, 108, 426-431.
[61] Geng, Q., et al. (2014) Meta-Analysis of the Effect of Statins on Renal Function. American Journal of Cardiology, 114, 562-570.
[62] Li, Y.B., et al. (2011) Effect of Simvastatin on Expression of Transforming Growth Factor-Beta and Collagen Type IV in Rat Mesangial Cells. Pharmacology, 88, 188-192.
[63] Rodrigues Diez, R., et al. (2010) Statins Inhibit Angiotensin II/Smad Pathway and Related Vascular Fibrosis, by a TGF-Beta-Independent Process. PLoS ONE, 5, e14145.
[64] Solini, A., et al. (2011) Angiotensin-II and Rosuvastatin Influence Matrix Remodeling in Human Mesangial Cells via Metalloproteinase Modulation. Journal of Hypertension, 29, 1930-1939.
[65] Ko, J.H., et al. (2012) HMG-CoA Reductase Inhibitors (Statins) Reduce Hypertrophic Scar Formation in a Rabbit Ear Wounding Model. Plastic and Reconstructive Surgery, 129, 252e-261e.
[66] Dinarvand, P., et al. (2013) Novel Approach to Reduce Postsurgical Adhesions to a Minimum: Administration of Losartan plus Atorvastatin Intraperitoneally. Journal of Surgical Research, 181, 91-98.
[67] Lalountas, M., et al. (2012) Postoperative Adhesion Prevention Using a Statin-Containing Cellulose Film in an Experimental Model. British Journal of Surgery, 99, 423-429.
[68] McGwin Jr., G., et al. (2004) Statins and Other Cholesterol-Lowering Medications and the Presence of Glaucoma. Archives of Ophthalmology, 122, 822-826.
[69] De Castro, D.K., et al. (2007) Effect of Statin Drugs and Aspirin on Progression in Open-Angle Glaucoma Suspects Using Confocal Scanning Laser Ophthalmoscopy. Clinical & Experimental Ophthalmology, 35, 506-513.
[70] Owen, C.G., et al. (2010) Hypotensive Medication, Statins, and the Risk of Glaucoma. Investigative Ophthalmology & Visual Science, 51, 3524-3530.
[71] Iskedjian, M., et al. (2009) Effect of Selected Antihypertensives, Antidiabetics, Statins and Diuretics on Adjunctive Medical Treatment of Glaucoma: A Population Based Study. Current Medical Research and Opinion, 25, 1879-1888.
[72] Garcia, I.M., et al. (2012) Caveolin-1-eNOS/Hsp70 Interactions Mediate Rosuvastatin Antifibrotic Effects in Neonatal Obstructive Nephropathy. Nitric Oxide, 27, 95-105.
[73] Tang, X.L., et al. (2011) Atorvastatin Therapy during the Peri-Infarct Period Attenuates Left Ventricular Dysfunction and Remodeling after Myocardial Infarction. PLoS ONE, 6, e25320.
[74] Villarreal Jr., G., et al. (2014) Pharmacological Regulation of SPARC by Lovastatin in Human Trabecular Meshwork Cells. Investigative Ophthalmology & Visual Science, 55, 1657-1665.
[75] Pahan, K., et al. (1997) Lovastatin and Phenylacetate Inhibit the Induction of Nitric Oxide Synthase and Cytokines in Rat Primary Astrocytes, Microglia, and Macrophages. Journal of Clinical Investigation, 100, 2671-2679.
[76] Krempler, K., et al. (2011) Simvastatin Improves Retinal Ganglion Cell Survival and Spatial Vision after Acute Retinal Ischemia/Reperfusion in Mice. Investigative Ophthalmology & Visual Science, 52, 2606-2618.
[77] Tanaka, S., et al. (2013) Statins Exert the Pleiotropic Effects through Small GTP-Binding Protein Dissociation Stimulator Upregulation with a Resultant Rac1 Degradation. Arteriosclerosis, Thrombosis, and Vascular Biology, 33, 1591-1600.
[78] Rao, P.V., et al. (2001) Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific Inhibitor Y-27632. Investigative Ophthalmology & Visual Science, 42, 1029-1037.
[79] Allal, C., et al. (2000) RhoA Prenylation Is Required for Promotion of Cell Growth and Transformation and Cytoskeleton Organization but Not for Induction of Serum Response Element Transcription. The Journal of Biological Chemistry, 275, 31001-31008.
[80] Lebowitz, P.F., Du, W. and Prendergast, G.C. (1997) Prenylation of RhoB Is Required for Its Cell Transforming Function but Not Its Ability to Activate Serum Response Element-Dependent Transcription. The Journal of Biological Chemistry, 272, 16093-16095.
[81] Ramos, R.F., Sumida, G.M. and Stamer, W.D. (2009) Cyclic Mechanical Stress and Trabecular Meshwork Cell Contractility. Investigative Ophthalmology & Visual Science, 50, 3826-3832.
[82] Honjo, M., et al. (2001) Effects of Protein Kinase Inhibitor, HA1077, on Intraocular Pressure and Outflow Facility in Rabbit Eyes. Archives of Ophthalmology, 119, 1171-8.
[83] Rao, P.V., et al. (2005) Expression of Dominant Negative Rho-Binding Domain of Rho-Kinase in Organ Cultured Human Eye Anterior Segments Increases Aqueous Humor Outflow. Molecular Vision, 11, 288-297.
[84] Tanihara, H., et al. (2013) Phase 1 Clinical Trials of a Selective Rho Kinase Inhibitor, K-115. JAMA Ophthalmology, 131, 1288-1295.
[85] Takanashi, Y., et al. (2001) Efficacy of Intrathecal Liposomal Fasudil for Experimental Cerebral Vasospasm after Subarachnoid Hemorrhage. Neurosurgery, 48, 894-900.
[86] Naraoka, M., et al. (2013) Suppression of the Rho/Rho-Kinase Pathway and Prevention of Cerebral Vasospasm by Combination Treatment with Statin and Fasudil after Subarachnoid Hemorrhage in Rabbit. Translational Stroke Research, 4, 368-374.
[87] Thieme, H., et al. (2000) Mediation of Calcium-Independent Contraction in Trabecular Meshwork through Protein Kinase C and Rho-A. Investigative Ophthalmology & Visual Science, 41, 4240-4246.
[88] Kameda, T., et al. (2012) The Effect of Rho-Associated Protein Kinase Inhibitor on Monkey Schlemm’s Canal Endothelial Cells. Investigative Ophthalmology & Visual Science, 53, 3092-3103.
[89] Lu, Z., et al. (2008) The Mechanism of Increasing Outflow Facility by Rho-Kinase Inhibition with Y-27632 in Bovine Eyes. Experimental Eye Research, 86, 271-281.
[90] Nobes, C.D. and Hall, A. (1995) Rho, Rac, and Cdc42 GTPases Regulate the Assembly of Multimolecular Focal Complexes Associated with Actin Stress Fibers, Lamellipodia, and Filopodia. Cell, 81, 53-62.
[91] Kato, T., et al. (2014) Rac1-Dependent Lamellipodial Motility in Prostate Cancer PC-3 Cells Revealed by Optogenetic Control of Rac1 Activity. PLoS ONE, 9, e97749.
[92] Sundaresan, M., et al. (1996) Regulation of Reactive-Oxygen-Species Generation in Fibroblasts by Rac1. Biochemical Journal, 318, 379-382.
[93] Farrell, S.M., et al. (2011) bFGF-Mediated Redox Activation of the PI3K/Akt Pathway in Retinal Photoreceptor Cells. European Journal of Neuroscience, 33, 632-641.
[94] Groeger, G., Quiney, C. and Cotter, T.G. (2009) Hydrogen Peroxide as a Cell-Survival Signaling Molecule. Antioxidants Redox Signaling, 11, 2655-2671.
[95] Rhee, S.G. (2006) Cell Signaling. H2O2, a Necessary Evil for Cell Signaling. Science, 312, 1882-1883.
[96] Takemoto, M., et al. (2001) Statins as Antioxidant Therapy for Preventing Cardiac Myocyte Hypertrophy. Journal of Clinical Investigation, 108, 1429-1437.
[97] McElnea, E.M., et al. (2011) Oxidative Stress, Mitochondrial Dysfunction and Calcium Overload in Human Lamina Cribrosa Cells from Glaucoma Donors. Molecular Vision, 17, 1182-1191.
[98] Sundaresan, P., et al. (2014) Whole-Mitochondrial Genome Sequencing in Primary Open-Angle Glaucoma Using Massively Parallel Sequencing Identifies Novel and Known Pathogenic Variants. Genetics in Medicine, Published Online.
[99] Schlotzer-Schrehardt, U. (2010) Oxidative Stress and Pseudoexfoliation Glaucoma. Klinische Monatsblätter für Augenheilkunde, 227, 108-113.
[100] Sacca, S.C. and Izzotti, A. (2008) Oxidative Stress and Glaucoma: Injury in the Anterior Segment of the Eye. Progress in Brain Research, 173, 385-407.
[101] Gherghel, D., et al. (2005) Systemic Reduction in Glutathione Levels Occurs in Patients with Primary Open-Angle Glaucoma. Investigative Ophthalmology & Visual Science, 46, 877-883.
[102] Ferreira, S.M., et al. (2004) Oxidative Stress Markers in Aqueous Humor of Glaucoma Patients. American Journal of Ophthalmology, 137, 62-69.
[103] Sacca, S.C., et al. (2007) Glaucomatous Outflow Pathway and Oxidative Stress. Experimental Eye Research, 84, 389-399.
[104] Maher, P. and Hanneken, A. (2005) The Molecular Basis of Oxidative Stress-Induced Cell Death in an Immortalized Retinal Ganglion Cell Line. Investigative Ophthalmology & Visual Science, 46, 749-757.
[105] Luksch, A., et al. (2000) Effects of Systemic NO Synthase Inhibition on Choroidal and Optic Nerve Head Blood Flow in Healthy Subjects. Investigative Ophthalmology & Visual Science, 41, 3080-3084.
[106] Polak, K., et al. (2007) Altered Nitric Oxide System in Patients with Open-Angle Glaucoma. Archives of Ophthalmology, 125, 494-498.
[107] Henry, E., et al. (2006) Altered Endothelin-1 Vasoreactivity in Patients with Untreated Normal-Pressure Glaucoma. Investigative Ophthalmology & Visual Science, 47, 2528-2532.
[108] Henry, E., et al. (1999) Peripheral Endothelial Dysfunction in Normal Pressure Glaucoma. Investigative Ophthalmology & Visual Science, 40, 1710-1714.
[109] Liao, J.K. (1994) Inhibition of Gi Proteins by Low Density Lipoprotein Attenuates Bradykinin-Stimulated Release of Endothelial-Derived Nitric Oxide. The Journal of Biological Chemistry, 269, 12987-12992.
[110] Alderson, L.M., et al. (1986) LDL Enhances Monocyte Adhesion to Endothelial Cells in Vitro. The American Journal of Pathology, 123, 334-342.
[111] Laufs, U. and Liao, J.K. (1998) Post-Transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase. The Journal of Biological Chemistry, 273, 24266-24271.
[112] Plenz, G.A., Hofnagel, O. and Robenek, H. (2004) Differential Modulation of Caveolin-1 Expression in Cells of the Vasculature by Statins. Circulation, 109, e7-e8.
[113] Thorleifsson, G., et al. (2010) Common Variants near CAV1 and CAV2 Are Associated with Primary Open-Angle Glaucoma. Nature Genetics, 42, 906-909.
[114] Overby, D.R., et al. (2014) Altered Mechanobiology of Schlemm’s Canal Endothelial Cells in Glaucoma. Proceedings of the National Academy of Sciences of the United States of America, 111, 13876-13881.
[115] Ulivieri, C. and Baldari, C.T. (2014) Statins: From Cholesterol-Lowering Drugs to Novel Immunomodulators for the Treatment of Th17-Mediated Autoimmune Diseases. Pharmacological Research, 88, 41-52.
[116] Gallego, B.I., et al. (2012) IOP Induces Upregulation of GFAP and MHC-II and Microglia Reactivity in Mice Retina Contralateral to Experimental Glaucoma. Journal of Neuroinflammation, 9, 92.
[117] Ebneter, A., et al. (2010) Microglial Activation in the Visual Pathway in Experimental Glaucoma: Spatiotemporal Characterization and Correlation with Axonal Injury. Investigative Ophthalmology & Visual Science, 51, 6448-6460.
[118] Johnson, E.C., et al. (2011) Cell Proliferation and Interleukin-6-Type Cytokine Signaling Are Implicated by Gene Expression Responses in Early Optic Nerve Head Injury in Rat Glaucoma. Investigative Ophthalmology & Visual Science, 52, 504-518.
[119] Haddadin, R.I., et al. (2009) SPARC-Null Mice Exhibit Lower Intraocular Pressures. Investigative Ophthalmology & Visual Science, 50, 3771-3777.
[120] Swaminathan, S.S., et al. (2013) Secreted Protein Acidic and Rich in Cysteine (SPARC)-Null Mice Exhibit More Uniform Outflow. Investigative Ophthalmology & Visual Science, 54, 2035-2047.
[121] Oh, D.J., et al. (2013) Overexpression of SPARC in Human Trabecular Meshwork Increases Intraocular Pressure and Alters Extracellular Matrix. Investigative Ophthalmology & Visual Science, 54, 3309-3319.
[122] Bollinger, K.E., et al. (2011) Quantitative Proteomics: TGFbeta(2) Signaling in Trabecular Meshwork Cells. Investigative Ophthalmology & Visual Science, 52, 8287-8294.
[123] Von Zee, C.L., et al. (2009) Increased RhoA and RhoB Protein Accumulation in Cultured Human Trabecular Meshwork Cells by Lovastatin. Investigative Ophthalmology & Visual Science, 50, 2816-2823.
[124] Osborne, N.N., et al. (2004) Retinal Ischemia: Mechanisms of Damage and Potential Therapeutic Strategies. Progress in Retinal and Eye Research, 23, 91-147.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.